Most vaccines are administered intramuscularly, although HIV or SARS-CoV-2 is infected via targeted mucous membranes with a new technique that has achieved strong antibody responses to these viruses in tests with mice and non-human primates.

A study led by American researchers and published Wednesday Science Translational Medicine It offers a new intranasal vaccination platform where immunizing proteins can be administered via the mucosal surface.

Although intranasal vaccines can elicit stronger and more protective antibody responses than injected ones, research has so far been limited due to poor uptake of the vaccine through mucosal linings.

However, the new technology offers a promising approach for delivering vaccines through the nose and other mucosal surfaces instead of traditional injections.

The research team, led by Brittany Hartwell of the Massachusetts Institute of Technology (MIT), created a strategy that allows immunostimulating proteins to travel across mucosal surfaces.

To do this, they used amf proteins, which consist of conjugated viral proteins that have a water-soluble end as they bind to albumin.

Albumin is a blood protein for CF that crosses the mucosa by interacting with the neonatal receptor and carries it bidirectionally across the mucosal epithelium, making it suitable as a mediator for vaccine delivery.

Amph can be formulated with the Env gp120 protein found on the outer envelope of HIV or the SARS-Cov2 receptor binding domain (RBD) protein that binds to human cells.

When administered intranasally to mice and macaques, it induces high concentrations of immunoglobulin G (IgG) and IgA antibodies in various mucosal tissues.

“These results may bode well for the possibility of a vaccine that will prevent HIV infection and have the potential to contribute to the target of a SARS-CoV-2 vaccine, whatever its variant,” said Francis Szoka of the University of California. article exploring the clinical outcomes of the study.